Recursion (NASDAQ: RXRX) is a clinical stage drug discovery company that combines automated imaging and artificial intelligence (AI) to rapidly identify therapeutic candidates via “phenomic” analysis.

To date, their development pipeline has produced four preclinical and five clinical assets. The company’s lead programs in Cerebral Cavernous Malformation (CCM) and Neurofibromatosis 2 (NF2) are both poised for Phase II trials. The company has secured partnerships with Takeda and Bayer, and is currently valued at over $1B. Recursion’s AI-enabled screening platform and impressive investor syndicate both suggest a strong potential to become a leader in the drug discovery space.